Silence Therapeutics (SLN) AI Stock Analysis

• Market Cap: $277.26M
• Dividend Yield: N/A
• Average Volume (3M): 101.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 116
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.15
• Shares Outstanding: 47,233,948
• 10 Day Avg. Volume: 169,902
• 30 Day Avg. Volume: 101,050
• PEG Ratio: 0.47
• Price to Book (P/B): 2.42
• Price to Sales (P/S): 7.51
• P/FCF Ratio: -4.79
• Enterprise Value/Market Cap: 0.58
• Enterprise Value/Revenue: 6.43
• Enterprise Value/Gross Profit: 6.93
• Enterprise Value/Ebitda: -2.48
• 1Y Price Target: $75.00
• Price Target Upside: 1177.68% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $6.00 ▲(2.21% Upside)

The score is mainly pressured by weak financial performance (widening losses and worsening cash burn alongside volatile/recently declining revenue) and bearish-to-neutral technicals (below key moving averages with negative MACD). Valuation provides limited support due to negative earnings and no dividend.

Positive Factors

Low leverage / balance sheet strength

Very low debt and positive equity provide durable financial flexibility, lowering refinancing and interest-rate risk. This strengthens the company's ability to fund ongoing R&D or bridge financing needs, supporting operations and partnership negotiations over the next several quarters.

Phase 2 enrollment completed

Completing Phase 2 enrollment materially reduces clinical execution risk and keeps the program on a definable timeline (readout expected Q3 2026). This advancement enhances the long-term probability of regulatory progress, partnerships, or milestone revenue events.

Diversified partnership/licensing revenue model

A revenue mix that includes collaborations, upfronts, milestones and royalties provides structural, contract-backed cash inflows that can de-risk funding for R&D. Such partner-driven funding reduces sole reliance on equity markets and supports sustained development spending.

Negative Factors

Worsening cash generation / cash burn

Persistently negative operating and free cash flow, with deterioration versus prior year, increases the company's dependence on external financing or partner receipts. Over a multi-quarter horizon this raises funding risk and the likelihood of dilutive financings or curtailed program spending.

Volatile, declining TTM revenue

Sharp TTM revenue decline and milestone-driven volatility make near-term cash flows unpredictable and impair the firm's ability to cover fixed R&D and SG&A costs. This structural revenue inconsistency complicates planning and increases execution risk for sustained operations.

Executive leadership turnover

The CEO departure and interim leadership create execution and fundraising risk at a critical development stage. Leadership changes can delay strategic decisions, slow partner negotiations or hiring of an applicable successor, potentially affecting trial commercialization and financing timelines.

Silence Therapeutics Business Overview & Revenue Model

Company Description

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

How the Company Makes Money

Silence Therapeutics generates revenue through multiple streams, including collaborations and partnerships with pharmaceutical companies for the development of RNA-based therapies. The company often engages in licensing agreements that provide upfront payments, milestone payments based on the progress of drug candidates, and royalties from any resulting sales of products developed through these collaborations. Additionally, Silence Therapeutics may receive funding through grants or government programs aimed at supporting innovative healthcare solutions. Their strategic partnerships with larger pharmaceutical entities enhance their financial stability and expand their research capabilities, contributing significantly to their earnings.

Silence Therapeutics Financial Statement Overview

Summary

Silence Therapeutics shows revenue growth but struggles with profitability due to negative EBIT and net income margins. The balance sheet is weak with negative equity, and cash flow challenges persist despite financing flexibility.

Income Statement

Silence Therapeutics has demonstrated significant revenue growth over the years, with a notable increase from 2023 to 2024. However, the company continues to face challenges with profitability, as evidenced by negative EBIT and net income margins. The consistent negative profit margins highlight a need for enhanced cost management or increased revenue to achieve profitability.

Balance Sheet

The company's balance sheet reveals a concerning negative stockholders' equity as of 2024, indicating financial instability. The debt-to-equity ratio is not favorable due to the negative equity, and although the company maintains substantial cash reserves, the high liabilities present a risk. Improving equity and managing liabilities are critical for financial health.

Cash Flow

Silence Therapeutics has managed significant financing cash flow, which supports its operations despite negative operating cash flow. The free cash flow has been consistently negative, reflecting ongoing cash challenges. However, the company's ability to secure financing offers some operational flexibility. Improving free cash flow is essential for sustainable growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	24.85M	43.26M	25.38M	21.66M	12.41M	5.48M
Gross Profit	23.04M	31.45M	15.06M	8.19M	4.96M	1.72M
EBITDA	-64.37M	-48.99M	-49.78M	-60.44M	-45.42M	-35.53M
Net Income	-62.67M	-45.31M	-43.27M	-50.33M	-39.41M	-32.55M
Balance Sheet
Total Assets	146.79M	202.63M	119.45M	107.50M	96.19M	85.97M
Cash, Cash Equivalents and Short-Term Investments	102.19M	147.33M	68.79M	71.14M	73.54M	37.45M
Total Debt	182.00K	117.00K	346.00K	446.00K	137.00K	341.00K
Total Liabilities	72.73M	68.61M	97.45M	85.43M	87.67M	76.91M
Stockholders Equity	74.06M	134.02M	21.99M	22.07M	8.53M	9.06M
Cash Flow
Free Cash Flow	-69.96M	-67.85M	-39.40M	-57.59M	7.39M	-11.29M
Operating Cash Flow	-69.85M	-67.64M	-39.35M	-57.04M	9.19M	-10.78M
Investing Cash Flow	73.47M	-21.97M	16.43M	-20.50M	11.71M	9.62M
Financing Cash Flow	19.89M	142.09M	25.16M	52.58M	41.45M	15.43M

Silence Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SLN, the sentiment is Neutral. The current price of 5.87 is below the 20-day moving average (MA) of 6.07, below the 50-day MA of 6.36, and above the 200-day MA of 5.43, indicating a neutral trend. The MACD of -0.17 indicates Positive momentum. The RSI at 43.91 is Neutral, neither overbought nor oversold. The STOCH value of 58.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SLN.

Silence Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABEO	60 Neutral	$281.25M	4.45	75.90%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SLN	47 Neutral	$277.26M	-3.51	―	―	―	―
VOR	47 Neutral	$323.62M	-0.04	―	―	―	-1072.48%
HUMA	45 Neutral	$220.02M	-4.78	―	―	―	82.23%
GALT	44 Neutral	$193.44M	-5.07	―	―	―	18.82%

Silence Therapeutics Corporate Events

Silence Therapeutics Appoints CFO Rhonda Hellums to Board

On December 18, 2025, Silence Therapeutics plc appointed its Executive Vice President and Chief Financial Officer, Rhonda Hellums, to the company’s Board of Directors as an executive director, with her initial term running until the end of the 2026 Annual General Meeting of Shareholders. Hellums will serve on the board without additional compensation and will not sit on any board committees, and the company emphasized that her appointment did not arise from any special arrangements, family relationships, or related-party transactions, underlining standard governance practices for stakeholders monitoring board independence and oversight.

The most recent analyst rating on (SLN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.

Silence Therapeutics Announces CEO Departure and Leadership Changes

On December 15, 2025, Silence Therapeutics announced the departure of Craig Tooman as CEO and Board member, effective December 14, 2025. Iain Ross, Chairman of the Board, has been appointed as interim principal executive officer, while James Ede-Golightly has rejoined the Board as a director. These leadership changes reflect the company’s ongoing commitment to advancing its commercial and scientific pipeline, with the company in strong financial and operational health.

The most recent analyst rating on (SLN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.

Silence Therapeutics Completes Enrollment for Phase 2 Study

On October 23, 2025, Silence Therapeutics announced the completion of patient enrollment in the SANRECO Phase 2 study of divesiran for treating polycythemia vera (PV). This milestone reflects the growing interest in divesiran, a first-in-class siRNA targeting TMPRSS6, which aims to maintain hematocrit levels below 45% without phlebotomies. The study’s results are expected in the third quarter of 2026, potentially impacting the treatment landscape for PV, a condition with significant unmet needs.

The most recent analyst rating on (SLN) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Silence Therapeutics stock, see the SLN Stock Forecast page.